- Merck shares surge anew on lung cancer advance, while Bristol-Myers stock plummetsMarketWatch
- Survival data boosts Merck’s Keytruda lead in lung cancerReuters
- Bristol-Myers has Farther to FallWall Street Journal
- I/O combos inch forward in pharma’s lung cancer questBioPharma Dive
- Merck Tightens Its Grip on the Lung-Cancer MarketBloomberg